Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 935919

De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment


Pinterić, Marija; Podgorski, Iva I.; Sobočanec, Sandra; Popović Hadžija, Marijana; Paradžik, Mladen; Dekanić, Ana; Marinović, Maja; Halasz, Mirna; Belužić, Robert; Davidović, Grazia et al.
De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment // Free radical research, 52 (2018), 6; 672, 684 doi:10.1080/10715762.2018.1462495 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 935919 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment

Autori
Pinterić, Marija ; Podgorski, Iva I. ; Sobočanec, Sandra ; Popović Hadžija, Marijana ; Paradžik, Mladen ; Dekanić, Ana ; Marinović, Maja ; Halasz, Mirna ; Belužić, Robert ; Davidović, Grazia ; Ambriović Ristov, Andreja ; Balog, Tihomir

Izvornik
Free radical research (1071-5762) 52 (2018), 6; 672, 684

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Hyperoxia ; MCF-7 ; mitochondrial function ; ROS ; sirtuin 3

Sažetak
Sirtuin 3 (Sirt3) has a promising role in cancer tumourigenesis and treatment, but there have been controversies about its role as oncogene or tumour suppressor in different types of cancer. Changes in its expression are associated with the excessive production of reactive oxygen species (ROS), thus contributing to mitochondrial dysfunction and age-related pathologies. Hyperoxic treatment (i.e. generator of ROS) was shown to support some tumourigenic properties, but finally suppresses growth of certain mammary carcinoma cells. Due to strikingly reduced Sirt3 level in many breast cancer cell lines, we aimed to clarify the effect of de novo Sirt3 expression upon hyperoxic treatment in the human MCF-7 breast cancer cells. De novo expression of Sirt3 decreased metabolic activity and cellular growth of MCF-7 cells, reduced expression of proangiogenic and epithelial mesenchymal transition genes, induced metabolic switch from glycolysis to oxidative phosphorylation, and decreased abundance of senescent cells. These effects were enhanced upon hyperoxic treatment: induction of DNA damage and upregulation of p53, with an increase of ROS levels followed by mitochondrial and antioxidant dysfunction, resulted in additional reduction of metabolic activity and inhibition of cellular growth and survival. The mitigation of tumorigenic properties and enhancement of the susceptibility of the MCF-7 breast cancer cells to the hyperoxic treatment upon de novo Sirt3 expression indicates that these factors, individually and in combination, should be further explored in vitro and particularly in vivo, as an adjuvant tumour therapy in breast cancer malignancies.

Izvorni jezik
Engleski

Znanstvena područja
Biologija



POVEZANOST RADA


Projekti:
HRZZ-IP-2014-09-4533 - Sirtuin3 kao posrednik mitohondrijske funkcije u estrogen-ovisnoj otpornosti na oksidativni stres i prehranu s visokim udjelom masti (SuMERA) (Balog, Tihomir, HRZZ - 2014-09) ( CroRIS)

Ustanove:
Institut "Ruđer Bošković", Zagreb

Poveznice na cjeloviti tekst rada:

doi www.tandfonline.com

Citiraj ovu publikaciju:

Pinterić, Marija; Podgorski, Iva I.; Sobočanec, Sandra; Popović Hadžija, Marijana; Paradžik, Mladen; Dekanić, Ana; Marinović, Maja; Halasz, Mirna; Belužić, Robert; Davidović, Grazia et al.
De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment // Free radical research, 52 (2018), 6; 672, 684 doi:10.1080/10715762.2018.1462495 (međunarodna recenzija, članak, znanstveni)
Pinterić, M., Podgorski, I., Sobočanec, S., Popović Hadžija, M., Paradžik, M., Dekanić, A., Marinović, M., Halasz, M., Belužić, R. & Davidović, G. (2018) De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment. Free radical research, 52 (6), 672, 684 doi:10.1080/10715762.2018.1462495.
@article{article, author = {Pinteri\'{c}, Marija and Podgorski, Iva I. and Sobo\v{c}anec, Sandra and Popovi\'{c} Had\v{z}ija, Marijana and Parad\v{z}ik, Mladen and Dekani\'{c}, Ana and Marinovi\'{c}, Maja and Halasz, Mirna and Belu\v{z}i\'{c}, Robert and Davidovi\'{c}, Grazia and Ambriovi\'{c} Ristov, Andreja and Balog, Tihomir}, year = {2018}, pages = {684}, DOI = {10.1080/10715762.2018.1462495}, chapter = {672}, keywords = {Hyperoxia, MCF-7, mitochondrial function, ROS, sirtuin 3}, journal = {Free radical research}, doi = {10.1080/10715762.2018.1462495}, volume = {52}, number = {6}, issn = {1071-5762}, title = {De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment}, keyword = {Hyperoxia, MCF-7, mitochondrial function, ROS, sirtuin 3}, chapternumber = {672} }
@article{article, author = {Pinteri\'{c}, Marija and Podgorski, Iva I. and Sobo\v{c}anec, Sandra and Popovi\'{c} Had\v{z}ija, Marijana and Parad\v{z}ik, Mladen and Dekani\'{c}, Ana and Marinovi\'{c}, Maja and Halasz, Mirna and Belu\v{z}i\'{c}, Robert and Davidovi\'{c}, Grazia and Ambriovi\'{c} Ristov, Andreja and Balog, Tihomir}, year = {2018}, pages = {684}, DOI = {10.1080/10715762.2018.1462495}, chapter = {672}, keywords = {Hyperoxia, MCF-7, mitochondrial function, ROS, sirtuin 3}, journal = {Free radical research}, doi = {10.1080/10715762.2018.1462495}, volume = {52}, number = {6}, issn = {1071-5762}, title = {De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment}, keyword = {Hyperoxia, MCF-7, mitochondrial function, ROS, sirtuin 3}, chapternumber = {672} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font